Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 26, 2020
Daily News
November 26, 2020
- Relugolix Nets Positive PIII Data in Endometriosis, ASKA Set to Seek Add’l Use in H1 2021
November 26, 2020
- Vibegron Fails in US PII Trial for IBS Pain: Urovant
November 26, 2020
- Shionogi, Nagasaki Univ., Kitasato Institute Join Forces on Antimalarial Drug Research
November 26, 2020
- Dupixent Auto-Injector Now Available: Sanofi
November 26, 2020
- Nippon Shinyaku Files Uptravi for CTEPH
November 26, 2020
- PM Says to Get COVID-19 Shot When His Turn Comes Around
November 26, 2020
- MOF Panel Issues FY2021 Budget Recommendation, Ups Tone on All-Product Drug Re-Pricing
November 26, 2020
- 3 Pharma Groups: Limit Scope of Off-Year Re-Pricing to Drugs with “Significantly Large Discrepancy Rates”
November 26, 2020
- MHLW Scrambling to Set Up Vaccination System for Ultracold-Chain Required COVID-19 Vaccine
November 26, 2020
- JPMA Concerned about COVID-19 Pandemic’s Impact on Efforts to Improve Distribution
November 26, 2020
- MHLW Formulates Package Strategy for SaMD Commercialization, Eyes Sakigake Scheme
November 26, 2020
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…